专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011109625A4 METHODS FOR DETERMINING RESPONSIVENESS TO A DRUG BASED UPON DETERMINATION OF RAS MUTATION AND/OR RAS AMPLIFICATION 审中-公开
标题翻译：用于根据确定RAS突变和/或RAS放大确定对药物的响应的方法
公开(公告)号：WO2011109625A4
公开(公告)日：2011-11-10
申请号：PCT/US2011027040
申请日：2011-03-03
申请人： TARGETED MOLECULAR DIAGNOSTICS LLC , BACUS SARAH S
发明人： BACUS SARAH S
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6876 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The present disclosure provides methods for predicting the sensitivity (e.g., responsiveness) of a cell and/or biological sample obtained from a subject (e.g., a human) to a drug (e.g., a DHFR inhibitor). Such methods may comprise determining the presence or absence of one or more Ras mutations and/or determining the presence or absence of an amplification of the Ras gene in the cell and/or biological sample. The methods may be used to predict the responsiveness of a subject to treatment with a drug.
摘要翻译：本公开提供了用于预测从受试者（例如人）获得的细胞和/或生物样品对药物（例如DHFR抑制剂）的敏感性（例如，反应性）的方法。这样的方法可以包括确定一个或多个Ras突变的存在或不存在和/或确定细胞和/或生物样品中Ras基因的扩增的存在或不存在。该方法可用于预测受试者对药物治疗的反应性。

2. 发明申请

WO2008024837A3 RAPID METHOD FOR DETECTING MUTATED GENES 审中-公开
标题翻译：用于检测突变基因的快速检测方法
公开(公告)号：WO2008024837A3
公开(公告)日：2008-05-02
申请号：PCT/US2007076517
申请日：2007-08-22
申请人： TARGETED MOLECULAR DIAGNOSTICS , BACUS SARAH S
发明人： BACUS SARAH S
IPC分类号： G01N33/53 , A61K31/52 , C12Q1/68 , G01N33/567 , G01N33/574
CPC分类号： G01N33/74 , G01N2333/485
摘要： The present invention is a rapid, specific, and sensitive method of detecting mutations in receptor tyrosine kinase genes in formalin fixed tissue embedded in paraffin blocks to detect mutations.
摘要翻译：本发明是检测在石蜡块中的福尔马林固定组织中受体酪氨酸激酶基因突变的快速，特异和灵敏的方法，以检测突变。

3. 发明申请

WO2005017493A3 BIOMARKERS IN CANCER 审中-公开
标题翻译：癌症生物标志物
公开(公告)号：WO2005017493A3
公开(公告)日：2007-12-06
申请号：PCT/US2004026434
申请日：2004-08-10
申请人： SMITHKLINE BEECHAM CORP , BACUS SARAH S , SPECTOR NEIL LEE
发明人： BACUS SARAH S , SPECTOR NEIL LEE
IPC分类号： G01N33/574 , A61K31/52 , G01N20060101
CPC分类号： G01N33/574 , G01N33/57484 , G01N2333/71 , G01N2333/91205
摘要： Biomarkers may be used in the treatment of cancer, and as an aid in clinical decision making regarding which anti-cancer therapy to use in a particular patient. Described herein are methods of assessing whether a subject with a solid tumor is suitable for treatment with a dual EGFR/erbB2 tyrosine kinase inhibitor, by assessing the relative localization of pERK or pAKT in tumor cells, and/or assessing pre-treatment tumor cell levels of ErbB2.
摘要翻译：生物标志物可用于治疗癌症，并可作为临床决策的辅助，用于在特定患者中使用哪种抗癌疗法。本文描述的是通过评估pERK或pAKT在肿瘤细胞中的相对定位和/或评估预处理的肿瘤细胞水平来评估具有实体瘤的受试者是否适合用双重EGFR / erbB2酪氨酸激酶抑制剂治疗的方法的ErbB2。

4. 发明申请

WO2004000094A3 PREDICTIVE MARKERS IN CANCER THERAPY 审中-公开
标题翻译：癌症治疗中的预测标记
公开(公告)号：WO2004000094A3
公开(公告)日：2007-06-14
申请号：PCT/US0312739
申请日：2003-04-24
申请人： SMITHKLINE BEECHAM CORP , BACUS SARAH S , HERRLE MYRA R , KIRK L EDWARD , SPECTOR NEIL L , STOCUM MICHAEL T , XIA WENLE
发明人： BACUS SARAH S , HERRLE MYRA R , KIRK L EDWARD , SPECTOR NEIL L , STOCUM MICHAEL T , XIA WENLE
IPC分类号： G01N33/574 , A61B20060101 , G01N33/50
CPC分类号： G01N33/5041 , A61K31/52 , G01N33/57484 , G01N2333/9121
摘要： Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein.
摘要翻译：提供了可用于药物应答试验的分子标记，用于帮助确定个体受试者的肿瘤是否响应于用EGF和/或erbB2抑制剂治疗。标记物包括磷酸化ERK蛋白。

5. 发明申请

WO2004000102A3 METHOD FOR PREDICTING RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPY 审中-公开
标题翻译：预防抗生殖因子受体指导治疗的方法
公开(公告)号：WO2004000102A3
公开(公告)日：2005-12-15
申请号：PCT/US0319698
申请日：2003-06-19
申请人： ABGENIX INC , IMMUNEX CORP , BACUS SARAH S , LOCKBAUM PAMELA , SCHWAB GISELA , YANG XIAO-DONG , LYNCH DAVID HASKETT
发明人： BACUS SARAH S , LOCKBAUM PAMELA , SCHWAB GISELA , YANG XIAO-DONG , LYNCH DAVID HASKETT
IPC分类号： A61B20060101 , A61K38/17 , A61K38/18 , C07H21/02 , C07H21/04 , C07K16/28 , C12N5/00 , C12N15/00 , C12P19/34 , C12Q1/68 , G01N33/53 , G01N33/536 , G01N33/541 , G01N33/574
CPC分类号： A61K38/1808 , A61K2039/505 , C07K16/2863
摘要： The invention provides methods for determining or predicting response to cancer therapy in an individual.
摘要翻译：本发明提供了确定或预测个体对癌症治疗的反应的方法。

6. 发明申请

WO2004000102A2 METHOD FOR PREDICTING RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPY 审中-公开
标题翻译：预防抗生殖因子受体指导治疗的方法
公开(公告)号：WO2004000102A2
公开(公告)日：2003-12-31
申请号：PCT/US2003/019698
申请日：2003-06-19
申请人： ABGENIX, INC. , IMMUNEX CORPORATION , BACUS, Sarah, S. , LOCKBAUM, Pamela , SCHWAB, Gisela , YANG, Xiao-dong , LYNCH, David Haskett
发明人： BACUS, Sarah, S. , LOCKBAUM, Pamela , SCHWAB, Gisela , YANG, Xiao-dong , LYNCH, David Haskett
IPC分类号： A61B
CPC分类号： A61K38/1808 , A61K2039/505 , C07K16/2863
摘要： The invention provides methods for determining or predicting response to cancer therapy in an individual.
摘要翻译：本发明提供了确定或预测个体对癌症治疗的反应的方法。

7. 发明申请

WO0179855A3 METHOD FOR QUANTIFICATION OF AKT PROTEIN EXPRESSION 审中-公开
标题翻译： AKT蛋白质表达定量方法
公开(公告)号：WO0179855A3
公开(公告)日：2003-02-06
申请号：PCT/US0112288
申请日：2001-04-16
申请人： VENTANA MED SYST INC , UNIV ILLINOIS , BACUS SARAH S , GUDKOV ANDREI
发明人： BACUS SARAH S , GUDKOV ANDREI
IPC分类号： G01N33/53 , C12N15/09 , C12Q1/68 , G01N33/48 , G01N33/483 , G01N33/574 , G01N33/68 , G01N37/00
CPC分类号： G01N33/6803 , G01N33/5008 , G01N33/5011 , G01N33/5091 , G01N33/57484 , G01N33/68 , G01N33/6845 , G01N2800/52
摘要： The invention provides methods for the detection and quantification of AKT proteins and their activation states in cells or tissue samples. Specifically, the invention provides methods for the detection and quantification of AKT1 or AKT2 proteins or their activated derivatives by combining immunohistochemical assays, calibrated by reference to other immunological, biochemical, or molecular biological assays, with an imaging system to quantify expression or activation levels of these proteins.
摘要翻译：本发明提供了在细胞或组织样品中检测和定量AKT蛋白及其活化状态的方法。具体地，本发明提供了通过结合通过参考其他免疫学，生物化学或分子生物学测定校准的免疫组织化学测定与成像系统来检测和定量AKT1或AKT2蛋白或其活化衍生物的方法，以量化表达或活化水平这些蛋白质。

8. 发明申请

WO2012088067A1 METHODS FOR PREDICTING AND/OR DETERMINING RESPONSIVENESS TO A HISTONE DEACETYLASE (HDAC) INHIBITOR 审中-公开
标题翻译：用于预测和/或确定对HISTONE DEACETYLASE（HDAC）抑制剂的响应的方法
公开(公告)号：WO2012088067A1
公开(公告)日：2012-06-28
申请号：PCT/US2011/066085
申请日：2011-12-20
申请人： QUINTILES TRANSNATIONAL CORPORATION , BACUS, Sarah S.
发明人： BACUS, Sarah S.
IPC分类号： A61K48/00 , G01N33/48
CPC分类号： G01N33/5023 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N2333/98 , G01N2800/7028
摘要： The present disclosure provides methods for predicting the sensitivity (e.g., responsiveness) of a cell and/or biological sample obtained from a subject to treatment with a histone deacetylase (HDAC) inhibitor. Such methods may comprise detecting the expression of one or more biomarkers including, one or more miRNAs (e.g., one or more of miR-17, miR-20a, miR18a, miR19a, miR-19b or miR92a) and/or c-myc and/or the presence of a c-myc amplification (e.g., 3, 4, 5, 6,7, 8, 9 or 10 copies of c-myc per cell), in the cell and/or biological sample.
摘要翻译：本公开提供了用于预测从受试者获得的细胞和/或生物样品对组蛋白脱乙酰酶（HDAC）抑制剂治疗的敏感性（例如，响应性）的方法。这样的方法可以包括检测一种或多种生物标志物的表达，包括一种或多种miRNA（例如，miR-17，miR-20a，miR18a，miR19a，miR-19b或miR92a中的一种或多种）和/或c-myc和 /或在细胞和/或生物样品中存在c-myc扩增（例如，每个细胞的3,4,5,6,7,8,9或10拷贝的c-myc）。

9. 发明申请

WO2007092932A8 BIVALENT ERBB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE 审中-公开
标题翻译：双重ERBB配体结合分子及其制备和使用方法
公开(公告)号：WO2007092932A8
公开(公告)日：2009-07-30
申请号：PCT/US2007061863
申请日：2007-02-08
申请人： TARGETED MOLECULAR DIAGNOSTICS , YEDA RES & DEV , BACUS SARAH S , HILL JASON E , YARDEN YOSEF , KOCHUPURAKKAL BOSE S
发明人： BACUS SARAH S , HILL JASON E , YARDEN YOSEF , KOCHUPURAKKAL BOSE S
IPC分类号： C12P21/06 , C07K1/00
CPC分类号： C07K14/475
摘要： A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding molecules act as traps to bind and sequester ligands, thus making them unavailable for binding to cellular ErbB receptors.
摘要翻译：公开了一种新的二价ErbB基配体结合分子及其制备和使用方法。结合分子可以是由重组DNA分子表达的蛋白质。蛋白质可以含有ErbB受体的两个细胞外结构域，它们都与ErbB受体配体结合。这些结合分子作为结合和螯合配体的陷阱，因此使得它们不能与细胞ErbB受体结合。

10. 发明申请

WO2007101191A3 COMPOSITIONS AND METHODS FOR REDUCING CELLULAR FAT AND FOR PREDICTING CARDIAC TOXICITY AND UPON TREATMENT WITH TYROSINE KINASE INHIBITORS 审中-公开
标题翻译：用于减少细胞脂肪并用于预防心脏病毒的组合物和方法以及使用酪氨酸激酶抑制剂治疗
公开(公告)号：WO2007101191A3
公开(公告)日：2007-12-13
申请号：PCT/US2007062871
申请日：2007-02-27
申请人： TARGETED MOLECULAR DIAGNOSTICS , BACUS SARAH S
发明人： BACUS SARAH S
IPC分类号： G01N33/53 , C12N15/09 , C12P13/22
CPC分类号： G01N33/5061 , G01N33/5091 , G01N2333/4706 , G01N2333/81 , G01N2800/52
摘要： Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for determining whether a potential drug is likely to produce a cardiotoxic effect. The methods involve analyzing lipid levels or the expression fatty acid oxidation enzymes, pAMP activated protein kinase, glucose uptake, to determine whether a fatty acid oxidation disorder is present. The identification of a fatty acid oxidation disorder can be used as a predictor of toxicity, especially cardiac toxicity, and as an indication that organ function should be carefully monitored if a drug such as a tyrosine kinase inhibitor is administered. Methods are also disclosed for protecting organs from metabolic stress and for the treatment of cells, such as adipocytes, to reduce their lipid content.
摘要翻译：公开了用于确定选择用于用各种激酶抑制剂治疗的患者（例如酪氨酸激酶抑制剂，尤其是erbB抑制剂如赫赛汀）是否会发生器官毒性，特别是心脏毒性的方法。此外，公开了用于确定潜在药物是否可能产生心脏毒性作用的方法。该方法包括分析脂质水平或表达脂肪酸氧化酶，pAMP活化蛋白激酶，葡萄糖摄取，以确定是否存在脂肪酸氧化障碍。脂肪酸氧化障碍的鉴定可以用作毒性的预测因子，特别是心脏毒性，并且作为如果施用诸如酪氨酸激酶抑制剂的药物，应该仔细监测器官功能的指征。还公开了用于保护器官免受代谢压力和用于治疗细胞如脂肪细胞以降低其脂质含量的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式